1. Clinical & Scientific Overview
Bisoprolol Fumarate (TIP-MED-000010, Reference Code [3.10]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Highly Cardioselective Beta-1 Adrenergic Blocker.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Aten (Zydus), Betacard (Torrent), Tenormin (Abbott)
Oral Film-Coated Tablets: 1.25 mg, 2.5 mg, 5 mg, 10 mg
3. Mechanism of Action & Pharmacodynamics
Highly Cardioselective Beta-1 Adrenergic Blocker acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Highly Cardioselective Beta-1 Adrenergic Blocker for Chronic stable heart failure with reduced ejection fraction (HFrEF); hypertension; chronic stable angina pectoris; rate control in atrial fibrillation / supraventricular arrhythmias..
4. Therapeutic Indications & Evidence-Supported Uses
- Chronic stable heart failure with reduced ejection fraction (HFrEF)
- hypertension
- chronic stable angina pectoris
- rate control in atrial fibrillation / supraventricular arrhythmias
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Heart Failure: Start at 1.25 mg once daily; titrate gradually over weeks (2.5 mg, 3.75 mg, 5 mg, 7.5 mg) to max 10 mg once daily. Hypertension/Angina: 2.5 mg–10 mg once daily (Max 20 mg/day). Follow physician instructions.
Administration & Meal Timing: With or without food (usually taken in the morning with or after breakfast). | Once daily in the morning.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal & Hepatic: Balanced 50% renal (unchanged) and 50% hepatic clearance! In mild-to-moderate renal or hepatic impairment, no adjustment is needed. In severe renal impairment (CrCl <20 mL/min) or severe hepatic impairment (Child-Pugh C), do not exceed 10 mg once daily.
Renal & Hepatic: Balanced 50% renal (unchanged) and 50% hepatic clearance! In mild-to-moderate renal or hepatic impairment, no adjustment is needed. In severe renal impairment (CrCl <20 mL/min) or severe hepatic impairment (Child-Pugh C), do not exceed 10 mg once daily.
Renal & Hepatic: Balanced 50% renal (unchanged) and 50% hepatic clearance! In mild-to-moderate renal or hepatic impairment, no adjustment is needed. In severe renal impairment (CrCl <20 mL/min) or severe hepatic impairment (Child-Pugh C), do not exceed 10 mg once daily.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in acute decompensated heart failure, cardiogenic shock, 2nd/3rd degree AV block, sick sinus syndrome, symptomatic bradycardia (<50 bpm), and severe bronchial asthma. Highest Beta-1 selectivity among common beta-blockers, hence safer (with caution) in mild-to-moderate COPD.
Key Clinical Precautions: Renal & Hepatic: Balanced 50% renal (unchanged) and 50% hepatic clearance! In mild-to-moderate renal or hepatic impairment, no adjustment is needed. In severe renal impairment (CrCl <20 mL/min) or severe hepatic impairment (Child-Pugh C), do not exceed 10 mg once daily.
8. Adverse Effects Profile
- Bradycardia, mild dizziness, cold extremities, fatigue, headache, sleep disturbances.
- Symptomatic bradycardia (<45 bpm), heart block, worsening heart failure during rapid up-titration, bronchospasm (rare at ≤10 mg), masked tachycardia in hypoglycaemia.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Verapamil, diltiazem, digoxin, ivabradine, and amiodarone increase risk of severe bradycardia and AV conduction delay
- Rifampicin slightly shortens bisoprolol half-life
- NSAIDs reduce antihypertensive effect
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Emphasise once-daily morning administration and never stopping suddenly. Because bisoprolol is highly Beta-1 selective, it is frequently chosen by cardiologists for patients who also have COPD or diabetes, though pulse rate and blood sugar should still be monitored regularly.
- Meal & Clock Timing Instruction: With or without food (usually taken in the morning with or after breakfast). (Once daily in the morning.)
- Missed Dose Protocol: Take as soon as remembered in the morning or early afternoon; if evening, skip and take the usual dose next morning. Never double the dose.
- Geriatric Dispensing Pearl: Well tolerated in elderly CGHS patients due to once-daily dosing and predictable 50:50 hepatorenal elimination. Start at 1.25 mg or 2.5 mg OD and check pulse at every refill.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 1.25 mg, 2.5 mg, 5 mg, 10 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.10] (p. 25)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.12] Hydrochlorothiazide (HCTZ) — Thiazide Diuretic (Distal Convoluted Tubule Na+/Cl- Cotransporter
- [3.13] Furosemide (Frusemide) — High-Ceiling Loop Diuretic (Na+-K+-2Cl- Cotransporter Inhibitor)
- [3.14] Torsemide (Torasemide) — Loop Diuretic (Pyridine-Sulfonylurea Derivative with Mild Anti-Al
- [3.15] Spironolactone — Potassium-Sparing Diuretic; Mineralocorticoid (Aldosterone) Recep
